PROOF-HD

Rekrutierung

INFORMATIONEN

FÖRDERER

CHDI Foundation, Inc.

TEILNEHMER

84

PROOF-HD ist eine klinische Studie der Phase 3, in der die Wirksamkeit und Sicherheit von Pridopidin bei Patienten im Frühstadium der Huntington-Krankheit untersucht wird. Pridopidin ist ein kleines Molekül, das von Prilenia zur Behandlung von neurodegenerativen Erkrankungen wie der Huntington-Krankheit entwickelt wurde.

Nach Angaben von Prilenia ist Pridopidin ein orales Medikament, das zweimal täglich in einer kleinen, leicht zu schluckenden Kapsel verabreicht wird und ins Gehirn und Rückenmark gelangt, wo es ein Protein namens Sigma-1-Rezeptor (S1R) aktiviert. Die Aktivierung des S1R durch Pridopidin verbessert die Ausscheidung toxischer Proteine, steigert die Energieproduktion und reduziert zellulären Stress und Entzündungen. Diese Mechanismen sind entscheidend für die Funktion und das Überleben eines Neurons.

Alter für die Studie geeignet

20 Jahre bis 65 Jahre (Erwachsene, Ältere Erwachsene)

Geschlecht für die Studie geeignet

Alle

Nimmt gesunde Freiwillige auf

Nein

  • Diagnose der Huntington-Krankheit auf der Grundlage klinischer Merkmale und des Vorhandenseins von ≥36 CAG
  • Wiederholungen im Huntingtin-Gen
    Diagnosesicherheitsniveau (DCL) von 4
  • HD im Erwachsenenalter mit Beginn der Anzeichen und Symptome im Alter von ≥18 Jahren
  • HD im Stadium 1 oder 2, definiert als ein UHDRS-TFC-Score von ≥7 bei der Untersuchung
  • Verwendung von Pridopidin innerhalb von 12 Monaten vor dem Baseline-Besuch.
  • Gentherapie zu jeder Zeit
  • Jeder schwerwiegende medizinische Zustand oder jede klinisch signifikante Labor- oder Vitalzeichenanomalie, die eine sichere Teilnahme des Patienten an der Studie und deren Durchführung ausschließt, z. B. eine signifikante Herzerkrankung innerhalb der letzten 12 Wochen vor Studienbeginn oder bestimmte Herzrhythmusstörungen in der Vorgeschichte
  • Vorgeschichte von Epilepsie oder Krampfanfällen innerhalb der letzten 5 Jahre
  • Schwangere oder Stillende, oder die Absicht, während der Studie schwanger zu werden

LÄNDER

LÄNDER

Österreich

TRIAL SITE: Medizinische Universität Innsbruck

Adress: Innsbruck

Contact: Dora Valent, Study Site Coordinator

Phone: 0512 504 83237
Email: dora.valent@tirol-kliniken.at

Tschechische Republik

TRIAL SITE:Centrum extrapyramidových onemocnění

Adress: Prague

Contact: Jiri Klempir, MD, Study Site Investigator
Tel:   +420  732 273 271
Email:  Jiri.Klempir@seznam.cz

Frankreich

TRIAL SITE: Centre Hospitalier Universitaire (CHU) Henri Mondor

Adress: Paris

TRIAL SITE: Centre Hospitalier Universitaire (CHU) Amiens-Picardie

Adress: Amiens

TRIAL SITE:Centre Hospitalier Universitaire (CHU) de Bordeaux

Adress: Bordeaux

Deutschland

TRIAL SITE: Euregional Huntington Center Aachen (EHZA) 

Adress: Aachen

Contact: Maha Sagar, Study Site Coordinator, Email: NeuroStudien@ukaachen.de Tel: +49 241 80 80697

TRIAL SITE: George Huntington Institut

Adress: Münster

Contact: Tel: +49 251 7887880
Email: info@ghi-muenster.de

TRIAL SITE: Huntington Center North Rhine-Westphalia,
Department of Neurology,
Ruhr-University Bochum,
St. Josef-Hospital Bochum

Adress: Bochum

Contact: Email: d.kaminski@klinikum-bochum.de
Tel.: +49-234-509-2703

TRIAL SITE: Kbo-Isar-Amper-Klinikum Taufkirchen (Vils)

Adress: Taufkirchen (Vils)

Contact: Michael Bachmaier, Study Site Coordinator
Email: Michael.Bachmaier@kbo.de
Tel: 08084-934-417

TRIAL SITE: University of Lübeck

Adress: Lübeck

Contact: Saruhi Surnaschjan, Study Site Coordinator 
Phone:+49 451 50043497
Email: saruhi.surnaschjan@neuro.uni-luebeck.de

TRIAL SITE: Ulm University

Adress: Ulm

Italien

TRIAL SITE: IRCCS Istituto delle Scienze Neurologiche di Bologna

Adress: Bologna

Contact: Tel: +393387367104
Email: unitastudiclinici@ausl.bologna.it

TRIAL SITE: Fondazione IRCCS Istituto Neurologico Carlo Besta

Adress: Milano

Contact: Tel: +39 02 23942519
Email: centroHD@istituto-besta.it

TRIAL SITE: CSS-Mendel Institute at IRCCS Casa Sollievo della Sofferenza Research Hospital

Adress: Roma

Contact: Tel: +39 06 44700887
Email: info@lirh.it

Die Niederlande

TRIAL SITE: Maastricht University

Adress: Maastricht 

Contact: Dr. Mayke Oosterloo, Study Site Investigator
Tel: 0031-(0)43-387 76 76, Email: expertisecentrumhuntington@mumc.nl

TRIAL SITE:Leiden University Medical Center

Adress: Leiden

Contact: Tel: 0031715265442 
Email: huntington@lumc.nl

Polen

TRIAL SITE: Szpital Specjalistyczny Swietego Wojciecha

Adress: Gdansk

Contact: Agnieszka Konkel, Study Site Coordinator
Tel: +48 609 952 555
Email: konkel1989@gmail.com

TRIAL SITE: Krakowska Akademia Neurologii

Adress: Krakow

Contact: Email: centrum@neurologia.org.pl 
Tel: +48 12 426 92 80

TRIAL SITE:Instytut Psychiatrii i Neurologii

Adress: Warsaw

Contact: Grzegorz Witkowski, Study Site Investigator
Email: gwitkowski@ipin.edu.pl
Phone: +48694904208

Spanien

TRIAL SITE:Hospital de la Santa Creu i Sant Pau

Adress: Barcelona

Contact: Dr. Jaime Kulisevsky
Email: JKulisevsky@santpau.cat
Tel: +34 649 14 23 60

TRIAL SITE: Fundacion Hospital Universitario La Fé

Adress: Valencia

Contact: Francisco Castera, Study Site Coordinator
Email: franciscocasteraenroll@gmail.com

Carmen PEIRO, Study Site Investigator

Email: cpeirov@gmail.com
Tel: Phone: +34 682893185

TRIAL SITE: Burgos Foundation for Health Research

Adress: Burgos

Contact: Tel:  +34 947 28 18 00 ext 35380
Email: jessicajrp@hubu.es

mcubo@saludcastillayleon.es

TRIAL SITE:Hospital Ramón y Cajal

Adress: Madrid

Contact: Email: joselopezsendon@hotmail.com
Tel: +34  638 158 849

Vereinigtes Königreich

TRIAL SITE: University of Aberdeen, Institute of Medical Sciences

Adress: Aberdeen (Scotland)

Contact: Stella Sihlabela, Study Site Coordinator
Tel: +44 1224 552120
Email: stella.sihlabela@nhs.scot

Resifina Seyara, Study Site Coordinator
Tel: +44 1224 552120
Email: resifina.seyara@nhs.scot

TRIAL SITE: Barberry National Centre for Mental Health

Adress: Birmingham (England)

TRIAL SITE: Cardiff University

Adress: Cardiff (Wales)

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring. 

 
 
new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.